Hyspec Medtech ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2018
N/A
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 11.4% 9.6% 7.0% 16.8%  
Credit score (0-100)  0 22 25 33 9  
Credit rating  N/A BB BB BBB BB  
Credit limit (kDKK)  0.0 -0.0 -0.0 0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2018
N/A
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  0 0 0 0 0  
Gross profit  0.0 -13.6 -23.2 -14.9 -14.8  
EBITDA  0.0 -13.6 -23.2 -14.9 -14.8  
EBIT  0.0 -13.6 -23.2 -14.9 -259  
Pre-tax profit (PTP)  0.0 -13.6 -25.3 -17.1 -263.7  
Net earnings  0.0 -10.5 -19.6 -13.3 -276.3  
Pre-tax profit without non-rec. items  0.0 -13.6 -25.3 -17.1 -264  

 
See the entire income statement

Balance sheet (kDKK) 
2018
N/A
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 -10.4 -30.0 56.7 -220  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0.0 36.3 53.9 144 1.8  

Net Debt  0.0 0.0 -9.9 -2.5 -1.8  
 
See the entire balance sheet

Volume 
2018
N/A
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 -13.6 -23.2 -14.9 -14.8  
Gross profit growth  0.0% 0.0% -71.2% 35.9% 0.8%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 36 54 144 2  
Balance sheet change%  0.0% 0.0% 48.5% 167.4% -98.8%  
Added value  0.0 -13.6 -23.2 -14.9 -14.8  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 33 2 94 -373  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 -1.0 -2.0 -3.0 -4.0  

Profitability 
2018
N/A
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 100.0% 100.0% 100.0% 1,751.7%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% -29.1% -35.6% -13.1% -141.6%  
ROI %  0.0% 0.0% 0.0% -52.5% -913.2%  
ROE %  0.0% -28.9% -43.5% -24.1% -945.9%  

Solidity 
2018
N/A
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Equity ratio %  0.0% -22.2% -35.8% 39.3% -99.2%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 42.4% 17.1% 11.9%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2018
N/A
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Quick Ratio  0.0 0.1 0.2 0.2 0.0  
Current Ratio  0.0 0.1 0.2 0.2 0.0  
Cash and cash equivalent  0.0 0.0 9.9 2.5 1.8  

Capital use efficiency 
2018
N/A
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 -43.6 -65.2 -72.3 -219.6  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2018
N/A
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0